Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single ...

Shares of Repare Therapeutics RPTX gained 8% on Monday after it announced dosing the first patient in an early-stage study ...

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several ...

The lab of one University of Illinois researcher is receiving a hefty grant, which will be used towards cancer research. On ...

Bacteria-based therapies represent an exciting breakthrough in cancer treatment, harnessing their remarkable ability to ...

T cell therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid ...

Shares of Aura Biosciences climbed after the company said it received positive early data for its cancer drug bel-sar. The stock rose 14% to $11.70 in early trading Friday, after hitting a new 52-week ...

Learn how cancer tissue biobanks and insights into solid tumor heterogeneity are transforming drug discovery and leading to ...

The first patient blood samples, just weeks away, will open a new chapter in medicine’s ongoing search for a therapy that ...

As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say ...

Plus, the program manager for community outreach at Jefferson’s Sidney Kimmel Cancer Center, Yawei Song, is trying to ...

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors ...